Lantheus Q3 revenue up 18.4% to $378.7M; adjusted EPS $1.70 beats prior year

Lantheus Holdings, Inc.

2024-Q3 EPS reported $4.55 revenue$1,142,800,000

GAAP net income $131.1M ($1.79 diluted EPS) vs $132.0M ($1.88) in Q3 2023.
PYLARIFY sales $259.8M (+20.6%); DEFINITY sales $77.0M (+14.3%).
Acquired NAV-4694, a Phase 3 beta-amyloid imaging agent; NDA planned for 2026.
CMS CY2025 final rule improves separate payment for diagnostic radiopharmaceuticals including PYLARIFY, effective Jan 1, 2025.
FY2024 guidance narrowed: revenue $1.51B-$1.52B; adj. EPS $6.65-$6.70, at higher end of prior range.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.